ArticleIJTLD open2025
15-year trends in efficacy and effectiveness of treatment outcomes in drug-resistant pulmonary TB.
Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and tolerability of linezolid to treat tuberculosis: a systematic review and meta-analysis.Respiratory research & clinical practice · 2026Pooled it
- Treatment outcomes and long-term relapse-free survival after multidrug-resistant tuberculosis treatment in Latvia: a retrospective national cohort study.The Lancet regional health. Europe · 2026Article
- Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.IJTLD open · 2026Review
- Tuberculosis notification trends and treatment outcomes in Bangladesh: findings from a National TB Program data, 2019-2021.BMC infectious diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study describes the evolution of treatment outcomes in drug-resistant (DR) pulmonary TB, focusing on efficacy and effectiveness.
methodsWe searched PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science reporting DR-TB regimens from 1 January 2009 to 8 May 2024 and performed a systematic literature review and meta-analysis.
resultsA gradual increase in success rates in the treatment of DR pulmonary TB was observed from 2009 to 2024 across all studies. In observational studies, the average treatment success rate for mono-resistant TB (non-rifampicin-resistant TB, RR-TB) was 82.9%, while the average treatment success rate for RR/multidrug-resistant TB (MDR-TB) was 68.4%, and that of pre-extensively drug-resistant TB (pre-XDR-TB) and XDR-TB was 54.4% with an increasing trend over time. The outcomes of experimental studies, which included fewer patients, demonstrated 69.6% treatment success for RR/MDR-TB, with higher rates for pre-XDR/XDR-TB (79.2%) and a mix of the two groups (85.8%). Significant geographic variations in outcome rates were observed across studies.
conclusionThe current study demonstrates a steady improvement in treatment outcomes for DR-TB after a long period of stagnation. However, new drugs and novel regimens are needed to maintain or further improve treatment outcomes in DR-TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.